FDA approves Gilead's once-daily HIV pill Bixlenvo for patients with limited options

The tablet combines bictegravir, the backbone of Gilead's blockbuster HIV pill Biktarvy, with lenacapavir, a first-in-class capsid inhibitor that has become a centerpiece of the company's long-term strategy for HIV treatment and prevention. According to Gilead, the approval makes Bixlenvo the first single-tablet regimen available for adults with HIV whose virus is suppressed but who are unable to use currently available one-pill treatment options. That population accounts for an estimated 5% or more of people living with HIV in the U.S., the company told CNBC.

The list price before discounts or rebates is $4,595 for a 30-day supply, in line with other daily single-tablet HIV treatments, Gilead said. People without health insurance may be eligible to receive Bixlenvo for free through the company's patient assistance program, while those with commercial or private insurance may get co-pay support through another savings program.

Dr. Jared Baeten, Gilead's head of clinical development and virology therapeutic area, said in an interview that the drug "fulfills an unmet need, particularly for individuals who are on complex regimens who just would not otherwise consolidate down to something really meaningful for them and prescribers." He added that it is also meaningful for people seeking new options, saying, "We want to build options that give people the opportunity to choose something that's going to work for them and work for them for the long haul."

There is no cure for HIV or AIDS, but many people can manage the disease with a single daily pill, a treatment approach Gilead helped pioneer two decades ago. However, some patients cannot use existing one-tablet options like Biktarvy because of drug resistance from older therapies, side effects, or interactions with other medications, and may need to take multiple pills a day with complicated dosing schedules. Baeten noted that this group tends to be older and have long treatment histories, with some having taken handfuls of pills about 25 years ago. HIV also accelerates aging-related complications such as heart disease, diabetes, and high cholesterol in that age group.

The new pill is also aimed at people doing well on a single-tablet regimen, including Biktarvy, who want to switch. Baeten stressed that Bixlenvo is not intended to replace Biktarvy, but to expand choices. HIV care is highly individualized, and long-term success often depends on finding a regimen that fits a patient's preferences and lifestyle.

Bixlenvo is part of Gilead's broader effort to build a range of lenacapavir-based options, including daily pills, weekly oral regimens, and long-acting injectables. Baeten said the goal is to give patients flexibility, adding that some prefer the certainty of once a day while others might want a six-month injection. Having more than one medicine is essential because HIV can become resistant to an initial treatment, and combining the two drugs allows the pill to "hit the virus in two different ways" with high efficacy and strong protection against resistance.

The approval is based on two Phase 3 trials that evaluated Bixlenvo in adults with HIV whose virus was already suppressed on treatment, including people who switched from Biktarvy or complex multi-tablet regimens. The first trial, ARTISTRY-1, specifically enrolled patients with long treatment histories and drug resistance; participants had a median age of 60 and were taking between two and 11 pills daily before switching. In both studies, the pill maintained viral suppression at rates comparable to patients' previous regimens at 48 weeks and was generally well tolerated, with no new safety concerns. The most common side effects reported in at least 2% of participants included [the article cuts off here, but I will not invent details].